<DOC>
	<DOCNO>NCT01208181</DOCNO>
	<brief_summary>This 2-part ( 6 week duration part ) , randomize , double-blind , placebo-controlled study participant rheumatoid arthritis . The hypothesis etoricoxib ( 60 mg 90 mg ) administration demonstrate superior efficacy compare placebo 6 week treatment , measure great mean improvement baseline Disease Activity Score C-Reactive Protein ( DAS-28 CRP ) , great mean improvement Patient Global Assessment Pain ( PGAP ) baseline 6 week treatment . Additionally , add benefit increase dose etoricoxib 60 mg 90 mg assess second part study .</brief_summary>
	<brief_title>A Two-Part , 12-Week Study Etoricoxib Treatment Rheumatoid Arthritis ( RA ) ( MK-0663-107 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Is male female ≥ 18 year age general good health ( RA ) Has American College Rheumatology Rheumatoid Clinical Response Criteria ( ACR ) Functional Class I , II , III Has diagnosis RA least 6 month ago least 16 year age diagnose Has history positive therapeutic benefit nonsteroidal antiinflammatory drug ( NSAIDs ) take NSAID regular basis therapeutic dose level anticipate undergo change study Has concurrent medical/arthritic disease could confound interfere evaluation efficacy Has history gastric biliary surgery ( include gastric bypass surgery ) small intestine surgery cause clinical malabsorption Has active peptic ( gastric duodenal ) ulcer history inflammatory bowel disease Has confirm medical diagnosis ischemic heart disease , cerebrovascular disease , peripheral artery occlusive disease Class IIIV congestive heart failure Has uncontrolled hypertension ( systolic &gt; 160 mm Hg diastolic &gt; 90 mm Hg ) Visit 1 Visit 2 Has clinical diagnosis hepatic insufficiency define ChildPugh score ≥5 Has estimate glomerular filtration rate ≤30 mL/min Has history neoplastic disease within 5 year ( exception : basal cell carcinoma carcinoma situ cervix ) Is allergic etoricoxib ; history significant clinical laboratory adverse experience associate etoricoxib ; hypersensitivity aspirin NSAIDs ; allergy acetaminophen/paracetamol Has personal family history inherit acquire bleed disorder Requires oral corticosteroid therapy excess equivalent 10 mg daily prednisone and/or stable dose least 4 week prior Visit 1 and/or whose dose expect remain stable study Treated Bcell deplete therapy within past 6 month anticipate treatment trial Is recreational illicit drug use , history within 5 year drug alcohol abuse/dependence ; Is morbidly obese ( define body mass index ≥40 kg/m^2 ) Is pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>